{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"4"}],"units":"Participants"}],"description":"To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as \\>20% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline. Objective Response is presented as the total # patients with PR or CR.","groups":[{"description":"MM-121: 12 mg/kg IV weekly in 4-week cycles Cetuximab: 400 mg/m2 IV one-time loading dose followed by 200 mg/m2 IV weekly maintenance doses","id":"OG000","title":"Part 1: Cohort 1"},{"description":"MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW","id":"OG001","title":"Part 1: Cohort 2a"},{"description":"MM-121: 12 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW","id":"OG002","title":"Part 1: Cohort 2b"},{"description":"MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW","id":"OG003","title":"Part 1: Cohort 3a"},{"description":"MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW","id":"OG004","title":"Part 1: Cohort 3b"},{"description":"MM-121: 40 mg/kg one time loading dose followed by 20 mg/kg IV QW Cetuximab: 400 mg/m2 one-time loading dose followed by 250 mg/m2 maintenance IV QW","id":"OG005","title":"Part 1: Cohort 4"},{"description":"MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW","id":"OG006","title":"Part 1: Expansion Cohort"},{"description":"MM-121: 20 mg/kg IV QW\n\nCetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW\n\nIrinotecan: 180 mg/m2 IV Q2W","id":"OG007","title":"Part 2: Cohort 1"},{"description":"MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW\n\nCetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW\n\nIrinotecan: 180 mg/m2 IV Q2W","id":"OG008","title":"Part 2: Cohort 2"},{"description":"MM-121: 20 mg/kg IV QW\n\nCetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW\n\nIrinotecan: 180 mg/m2 IV Q2W","id":"OG009","title":"Part 2: Expansion Cohort"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Patients were assessed for objective response from time of first dose through treatment termination, the longest treatment duration being 48.1 weeks","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"participants with objective response"}